European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]met
Community Register of medicinal products
Community register of orphan medicinal products | GRANTED |
Product information |
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
| EU orphan designation number: | EU/3/12/1080
|
| Active ingredient: | 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
| Indication: | Treatment of chronic lymphocytic leukaemia |
| Sponsor: | AbbVie Ltd
Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berks, SL6 4XE, United Kingdom |
Public summary of scientific opinion
European Commission procedures
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 11/12/2012 | Centralised Orphan - Designation | EMA/OD/124/12 | (2012)9399 of 06/12/2012 |